[11C]‐DASB, a tool for in vivo measurement of SSRI‐induced occupancy of the serotonin transporter: PET characterization and evaluation in cats
暂无分享,去创建一个
Sylvain Houle | Alan A. Wilson | Nathalie Ginovart | S. Houle | N. Ginovart | D. Hussey | Jeffrey H Meyer | Alan A Wilson | Doug Hussey | J. Meyer | J. Meyer
[1] I. Podreka,et al. β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo , 2005, Journal of Neural Transmission / General Section JNT.
[2] C. Halldin,et al. In vitro and in vivo characterisation of nor-β-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain , 1997, European Journal of Nuclear Medicine.
[3] P. Celada,et al. Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.
[4] Sylvain Houle,et al. In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.
[5] Alan A. Wilson,et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. , 2001, The American journal of psychiatry.
[6] Alan A. Wilson,et al. Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] S. Houle,et al. Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography: Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of (11)C-Labeled 2-(Phenylthio)araalkylamines. , 2000, Journal of medicinal chemistry.
[8] G. Baker,et al. Failure to detect amphetamine or 1-amino-3-phenylpropane in humans or rats receiving the MAO inhibitor tranylcypromine. , 2000, Journal of affective disorders.
[9] Yann Hode,et al. Brain Pharmacokinetics and Tissue Distribution In Vivo of Fluvoxamine and Fluoxetine by Fluorine Magnetic Resonance Spectroscopy , 2000, Neuropsychopharmacology.
[10] Alan A. Wilson,et al. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.
[11] M Slifstein,et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] P. Renshaw,et al. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. , 2000, The American journal of psychiatry.
[13] J Sandell,et al. Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development. , 2000, Nuclear medicine and biology.
[14] Alan A. Wilson,et al. Radiotracer synthesis from [(11)C]-iodomethane: a remarkably simple captive solvent method. , 2000, Nuclear medicine and biology.
[15] Alexander Neumeister,et al. [123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder , 2000, Biological Psychiatry.
[16] H. Sitte,et al. Characterization of Carrier‐Mediated Efflux in Human Embryonic Kidney 293 Cells Stably Expressing the Rat Serotonin Transporter: A Superfusion Study , 2000, Journal of neurochemistry.
[17] Sylvain Houle,et al. Radiosynthesis of carbon‐11 labelled N‐methyl‐2‐(arylthio)benzylamines: potential radiotracers for the serotonin reuptake receptor , 1999 .
[18] P. Acton,et al. Single-photon emission tomography imaging of serotonin transporters in the nonhuman primate brain with [123I]ODAM , 1999, European Journal of Nuclear Medicine.
[19] P. Acton,et al. A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I]IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol. , 1999, Journal of medicinal chemistry.
[20] S. Kasper,et al. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment , 1999, European Neuropsychopharmacology.
[21] Linda Carpenter,et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography , 1998, Biological Psychiatry.
[22] Roger N. Gunn,et al. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals , 1998, European Journal of Nuclear Medicine.
[23] R. Blakely,et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.
[24] C Burger,et al. Requirements and implementation of a flexible kinetic modeling tool. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] Christer Halldin,et al. Effect of reserpine‐induced depletion of synaptic dopamine on [11C]Raclopride binding to D2‐dopamine receptors in the monkey brain , 1997, Synapse.
[26] P. Hof,et al. Autoradiographic distribution of [3H]paroxetine binding sites in the cat brain , 1997 .
[27] S. Preskorn,et al. Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors , 1997, Clinical pharmacokinetics.
[28] A. Lammertsma,et al. Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.
[29] A. Schmoldt,et al. One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. , 1996, Journal of analytical toxicology.
[30] S. Cheetham,et al. [3H]Nisoxetine—A radioligand for noradrenaline reuptake sites: Correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments , 1996, Neuropharmacology.
[31] S. Loft,et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine , 1996, European Journal of Clinical Pharmacology.
[32] P. Hof,et al. [3H]Nisoxetine binding sites in the cat brain: An autoradiographic study , 1995, Neuroscience.
[33] H N Wagner,et al. Positron Emission Tomography of 5-HT Transporter Sites in the Baboon Brain with [11C]McN5652 , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[34] Zsolt Szabo,et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652 , 1995, Synapse.
[35] F. Artigas,et al. Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain. , 1994, European journal of pharmacology.
[36] M. Kuhar,et al. Secondary amine analogues of 3 beta-(4'-substituted phenyl)tropane-2 beta-carboxylic acid esters and N-norcocaine exhibit enhanced affinity for serotonin and norepinephrine transporters. , 1994, Journal of medicinal chemistry.
[37] Jean Logan,et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.
[38] J. Hyttel. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs) , 1994, International clinical psychopharmacology.
[39] C. Nemeroff,et al. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. , 1994, Clinical chemistry.
[40] L. Gram. Drug therapy : fluoxetine , 1994 .
[41] S. Wrighton,et al. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. , 1993, The Journal of pharmacology and experimental therapeutics.
[42] Marc Laruelle,et al. SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates , 1993, Synapse.
[43] J S Fowler,et al. Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.
[44] J. Małyszko,et al. Serotonergic measures in blood and brain and their correlations in rats treated with tranylcypromine, a monoamine oxidase inhibitor. , 1993, The Japanese journal of physiology.
[45] G. Tucker,et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. , 1992, British journal of clinical pharmacology.
[46] R. Myers,et al. Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.
[47] F I Carroll,et al. High‐affinity binding of [125I]RTI‐55 to dopamine and serotonin transporters in rat brain , 1992, Synapse.
[48] G. Sedvall,et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.
[49] S. Tejani-butt. [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. , 1992, The Journal of pharmacology and experimental therapeutics.
[50] M. Thase,et al. Plasma Tranylcypromine: Relationship to Pharmacokinetic , 1990 .
[51] M. Thase,et al. Plasma Tranylcypromine: Relationship to Pharmacokinetic Variables and Clinical Antidepressant Actions , 1990, Journal of clinical psychopharmacology.
[52] S. Holte,et al. Evaluation of the Karolinska new positron camera system; the Scanditronix PC2048-15B , 1990 .
[53] P. Benfield,et al. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. , 1986, Drugs.
[54] A. Uzan,et al. Caractérisation biochimique et étude par autoradiographie quantitative des sites de fixation de l'indalpine, un inhibiteur de la récapture de 5-HT, dans le cerveau de chat , 1985 .
[55] D. Wong,et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. , 1982, The Journal of pharmacology and experimental therapeutics.
[56] P. Kragh‐Sørensen,et al. The kinetics of citalopram: single and multiple dose studies in man. , 2009, Acta pharmacologica et toxicologica.
[57] G. Reynolds,et al. Effects of tranylcypromine stereoisomers on monamine oxidation in man. , 1980, British journal of clinical pharmacology.
[58] P. Baumann,et al. Neurobiochemical Aspects of Maprotiline (Ludiomil®) Action , 1979, The Journal of international medical research.
[59] J. Aronson,et al. Tranylcypromine (‘Parnate’) overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma , 1979, Psychological Medicine.
[60] D. Wong,et al. Effect of nisoxetine on uptake of catecholamines in synaptosomes isolated from discrete regions of rat brain. , 1976, Biochemical pharmacology.
[61] D. Wong,et al. dl-N-methyl-3-(o-methoxyphenoxy)-3-phenylpropylamine hydrochloride, Lilly 94939, a potent inhibitor for uptake of norepinephrine into rat brain synaptosomes and heart. , 1975, Life sciences.
[62] M. Staehelin,et al. Blockade of noradrenaline uptake by 34276-Ba, a new antidepressant drug. , 1971, Biochemical pharmacology.